AXGN

55.7501.06%
JH

John H. Johnson

Independent Director

Mr. John H. Johnson is Director at Alpheus Medical, Inc. He serves as Operating Partner at HealthQuest Capital, a role he joined in June 2023. He serves as Chairman of the Board at Verastem, Inc. since December 2025. He also serves as Executive Chairman of Molina Information Systems, LLC, Independent Director of Portola Pharmaceuticals, Inc. since March 2014, Lead Independent Director of Sucampo Pharmaceuticals, Inc. since December 10, 2014, Independent Director of AxoGen, Inc. since July 19, 2021, Independent Director of Verastem, Inc. since April 2020, Independent Non-Executive Director of Xeris Biopharma Holdings, Inc. since October 2021, Chairman of VirMedica, Inc., Chairman of Cortendo AB since March 2015, Operating Advisor of US Healthcare of Cobepa S.A. since December 2020 and Director of Real Chemistry, Inc. since April 24, 2017. He focuses on Healthcare. He has more than three decades of experience across operating and investing. He served as Executive Chairman at Applied Therapeutics, Inc. from December 20, 2024 until November 2025. He was Chief Executive Officer of Reaction Biology Corporation from March 16, 2022 to July 2025. Prior to that, he was Chief Executive Officer of Strongbridge Biopharma PLC. He was CEO and Director of Strongbridge Biopharma plc from July 02, 2020. He was Executive Chairman and CEO of Strongbridge Biopharma plc from July 07, 2020 to July 2020. He was Executive Chairman of Strongbridge Biopharma plc from November 01, 2019 to July 07, 2020. He was Executive Chairman of Strongbridge Biopharma plc from March 17, 2015 to November 01, 2019. He has held executive management roles at leading global corporations, including Johnson and Johnson, where he spent the majority of his career and served as Company Group Chairman of Biopharmaceuticals. He was responsible for the Johnson and Johnson Biotechnology, Immunology and Oncology commercial businesses. He also served as President of Eli Lilly and Company's Worldwide Oncology Unit. He was Senior Vice President and President of Oncology Business Unit of Eli Lilly and Company from November 01, 2009 to January 28, 2011. He was President of Global Oncology Business Unit - Eli Lilly and Company of ImClone Systems LLC from August 27, 2007 to November 21, 2008. He served as Chief Executive Officer and a member of ImClone’s Board of Directors. From 2005 to 2007, Mr. Johnson served as Company Group Chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. He was Independent Non-Executive Chairman of the Board of Autolus Therapeutics plc from September 15, 2021 until April 1, 2024. He was Non-Executive Chairman of the Board of Autolus Therapeutics plc from September 15, 2021. From January 2012 until August 2014, he served as President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. He was Chief Executive Officer, President and Director of Savient Pharmaceuticals, Inc. from January 31, 2011 to February 01, 2012. He was Director of AVEO Pharmaceuticals, Inc. from February 01, 2018 to February 2019. He was Acting Chief Executive Officer of Melinta Therapeutics, LLC from August 05, 2019 to August 28, 2019. He was Chief Executive Officer of Melinta Therapeutics, LLC from February 22, 2019 to August 05, 2019 and served as its Director from October 22, 2018 to August 05, 2019. He was Interim Chief Executive Officer of Melinta Therapeutics, LLC from October 22, 2018 to February 22, 2019. He was Director of Melinta Therapeutics, LLC until October 22, 2018. He was Director of Cempra, Inc., which he joined in June 2009. He was Chairman of the Board of Corcept Therapeutics Incorporated, which he joined in March 2015. He was Director of Ocera Therapeutics, Inc. until July 15, 2013. He was Independent Director of Histogenics Corporation from November 2013 to February 27, 2019. He was Chairman of Tranzyme, Inc., which he joined in November 2010. He was Chairman of the Board of Tranzyme Pharma, Inc. He was Director of BioNJ Inc. He has served on several boards, including two private equity-backed company boards through successful exits, BioAgilytix and W2O. He has also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America and as a member of the Health Section Governing Board of Biotechnology Industry Organization. He holds a Bachelor of Science in Education from East Stroudsburg University and a Master of Business Administration from Simon Graduate School of Business at The University of Rochester.

公司职务